Atara Biotherapeutics Inc ATRA.OQ ATRA.O is expected to show a fall in quarterly revenue when it reports results on March 5 (estimated) for the period ending December 31 2025
The Thousand Oaks California-based company is expected to report a 93.1% decrease in revenue to $2.247 million from $32.75 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Atara Biotherapeutics Inc is for a loss of 37 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Atara Biotherapeutics Inc is $6.00, about 22.2% above its last closing price of $4.91
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.82 | -0.86 | -0.32 | Beat | 62.8 |
Jun. 30 2025 | -0.32 | -0.46 | 0.19 | Beat | 141.3 |
Mar. 31 2025 | -1.96 | -1.98 | 3.50 | Beat | 276.8 |
Dec. 31 2024 | -3.76 | -3.58 | -1.19 | Beat | 66.7 |
Sep. 30 2024 | -2.11 | -1.93 | -2.93 | Missed | -51.6 |
Jun. 30 2024 | -1.38 | -1.56 | -3.10 | Missed | -98.4 |
Mar. 31 2024 | -6.17 | -6.41 | -5.75 | Beat | 10.3 |
Dec. 31 2023 | -7.75 | -12.05 | -14.00 | Missed | -16.2 |
This summary was machine generated March 3 at 11:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)